


Amendment to the Claims


The claimed invention is:

1. (Currently Amended) A compound of formula (Ia), (Ib), or (Ic):



or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate or solvate thereof, wherein:

R¹ is a group of the formula



~~saturated, unsaturated, or aromatic C₃-C₂₀ mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S, wherein R¹ can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C₁-C₆)alkyl, perhalo(C₁-C₆)alkyl, perhalo(C₁-C₆)alkoxy,~~

(C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, hydroxy, oxo, mercapto, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, (C₅-C₁₀)aryl or (C₅-C₁₀)heteroaryl, (C₅-C₁₀)aryloxy or (C₅-C₁₀)heteroaryloxy, (C₅-C₁₀)ar(C₁-C₆)alkyl or (C₅-C₁₀)heteroar(C₁-C₆)alkyl, (C₅-C₁₀)ar(C₁-C₆)alkoxy or (C₅-C₁₀)heteroar(C₁-C₆)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C₁-C₆)alkyl, (C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl, (C₅-C₁₀)heterocyclyl(C₁-C₆)alkyl, (C₁-C₆)alkyl- and di(C₁-C₆)alkylamino, cyano, nitro, carbamoyl, (C₁-C₆)alkylcarbonyl, (C₁-C₆)alkoxycarbonyl, (C₁-C₆)alkylaminocarbonyl, di(C₁-C₆)alkylaminocarbonyl, (C₅-C₁₀)arylcarbonyl, (C₅-C₁₀)aryloxycarbonyl, (C₁-C₆)alkylsulfonyl, and (C₅-C₁₀)arylsulfonyl;

each R³ is independently selected from the group consisting of: hydrogen, halo, halo(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₅-C₁₀)heteroaryl, (C₅-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₅-C₁₀)heteroaryl-O-, (C₅-C₁₀)heterocyclic-O-, (C₃-C₁₀)cycloalkyl-O-, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, O₂N-, NC-, amino, Ph(CH₂)₁₋₆HN-, (C₁-C₆)alkyl HN-, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-SO₂-NH-, amino(C=O)-, aminoO₂S-, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[((C₁-C₆)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C₁-C₆)alkyl)-N]-, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, (C₅-C₁₀)heteroaryl-(C=O)-, (C₅-C₁₀)heterocyclic-(C=O)-, (C₃-C₁₀)cycloalkyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, H₂N(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C₁-C₆)alkyl)-N]-(C=O)-, (C₅-C₁₀)heteroaryl-NH-(C=O)-, (C₅-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)- and (C₁-C₆)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R³ is optionally substituted by at least one substituent independently selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, halo, H₂N-, Ph(CH₂)₁₋₆HN-, and (C₁-C₆)alkylHN-;

s is an integer from one to five;

and

R^6 is selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, (C_5-C_{10}) heteroaryl, (C_5-C_{10}) heterocyclic, (C_3-C_{10}) cycloalkyl, (C_1-C_6) alkyl-(SO_2)-, phenyl-(SO_2)-, $H_2N-(SO_2)$ -, (C_1-C_6) alkyl-NH-(SO_2)-, $((C_1-C_6)$ alkyl) $_2$ N-(SO_2)-, phenyl-NH-(SO_2)-, (phenyl) $_2$ N-(SO_2)-, (C_1-C_6) alkyl-($C=O$)-, phenyl-($C=O$)-, (C_5-C_{10}) heteroaryl-($C=O$)-, (C_5-C_{10}) heterocyclic-($C=O$)-, (C_3-C_{10}) cycloalkyl-($C=O$)-, (C_1-C_6) alkyl-O-($C=O$)-, (C_5-C_{10}) heterocyclic-O-($C=O$)-, (C_3-C_{10}) cycloalkyl-O-($C=O$)-, $H_2N-(C=O)$ -, (C_1-C_6) alkyl-NH-($C=O$)-, phenyl-NH-($C=O$)-, (C_5-C_{10}) heteroaryl-NH-($C=O$)-, (C_5-C_{10}) heterocyclic-NH-($C=O$)-, (C_3-C_{10}) cycloalkyl-NH-($C=O$)-, $((C_1-C_6)$ alkyl) $_2$ N-($C=O$)-, (phenyl) $_2$ N-($C=O$)-, phenyl-[$((C_1-C_6)$ alkyl)-N]-($C=O$)-, (C_5-C_{10}) heteroaryl-[$((C_1-C_6)$ alkyl)-N]-($C=O$)-, (C_5-C_{10}) heterocyclic-[$((C_1-C_6)$ alkyl)-N]-($C=O$)-, and (C_3-C_{10}) cycloalkyl-[$((C_1-C_6)$ alkyl)-N]-($C=O$)-;

where alkyl, alkenyl, alkynyl, phenyl, benzyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^6 is optionally substituted with at least one moiety independently selected from the group consisting of halo, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, perhalo(C_1-C_6)alkyl, (C_3-C_{10}) cycloalkyl, phenyl, benzyl, (C_5-C_{10}) heterocyclic, (C_5-C_{10}) heteroaryl, (C_1-C_6) alkyl- SO_2 -, formyl, NC-, (C_1-C_6) alkyl-($C=O$)-, (C_3-C_{10}) cycloalkyl-($C=O$)-, phenyl-($C=O$)-, (C_5-C_{10}) heterocyclic-($C=O$)-, (C_5-C_{10}) heteroaryl-($C=O$)-, HO-($C=O$)-, (C_1-C_6) alkyl-O-($C=O$)-, (C_3-C_{10}) cycloalkyl-O-($C=O$)-, (C_5-C_{10}) heterocyclic-O-($C=O$)-, (C_1-C_6) alkyl-NH-($C=O$)-, (C_3-C_{10}) cycloalkyl-NH-($C=O$)-, phenyl-NH-($C=O$)-, (C_5-C_{10}) heterocyclic-NH-($C=O$)-, (C_5-C_{10}) heteroaryl-NH-($C=O$)-, $((C_1-C_6)$ alkyl) $_2$ N-($C=O$)-, phenyl-[$((C_1-C_6)$ alkyl)-N]-($C=O$)-, hydroxy, (C_1-C_6) alkoxy, perhalo(C_1-C_6)alkoxy, (C_3-C_{10}) cycloalkyl-O-, phenoxy, (C_5-C_{10}) heterocyclic-O-, (C_5-C_{10}) heteroaryl-O-, (C_1-C_6) alkyl-($C=O$)-O-, (C_3-C_{10}) cycloalkyl-($C=O$)-O-, phenyl-($C=O$)-O-, (C_5-C_{10}) heterocyclic-($C=O$)-O-, (C_5-C_{10}) heteroaryl-($C=O$)-O-, O_2N -, amino, (C_1-C_6) alkylamino, $((C_1-C_6)$ alkyl) $_2$ amino, formamidyl, (C_1-C_6) alkyl-($C=O$)-NH-, (C_3-C_{10}) cycloalkyl-($C=O$)-NH-, phenyl-($C=O$)-NH-, (C_5-C_{10}) heterocyclic-($C=O$)-NH-, (C_5-C_{10}) heteroaryl-($C=O$)-NH-, (C_1-C_6) alkyl-($C=O$)-[$((C_1-C_6)$ alkyl)-N]-, phenyl-($C=O$)-[($C_1-C_6)$ alkyl-N]-,

(C₁-C₆)alkyl-SO₂NH-, (C₃-C₁₀)cycloalkyl-SO₂NH-, phenyl-SO₂NH-, (C₅-C₁₀)heterocyclic-SO₂NH- and (C₅-C₁₀)heteroaryl-SO₂NH-;

wherein the phenyl moiety of a R⁶ substituent is optionally further substituted with at least one radical independently selected from the group consisting of halo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, perfluoro(C₁-C₆)alkyl and perfluoro(C₁-C₆)alkoxy,

~~with the proviso that R⁺ is not a naphthyl or phenyl¹; and~~

~~with the proviso that when R⁺ is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members containing up to three N atoms, said N is other than NH or NC₁-alkyl or if said N is NH or NC₁-alkyl, then R⁺ must be further substituted²; and~~

~~with the proviso that when R⁺ is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members containing 1-3 heteroatoms independently selected from O and S, then R⁺ must be further substituted.³~~

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Original) A compound of claim 1, wherein s is one to two; R³ is hydrogen or (C₁-C₆)alkyl; and R⁶ is H, (C₁-C₆)alkyl, or (C₃-C₁₀)cycloalkyl.

10. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

11. (Cancelled)

12. (Cancelled)

13. (New) A compound 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof.
14. (New) A pharmaceutical composition comprising 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.